Danish maker of obesity drugs to replace Lars Fruergaard Jørgensen, saying new leadership is needed as shares slump 50% in ...

Novo Nordisk today announced changes to its executive leadership and Board of Directors. As per mutual agreement with the ...

Jørgensen will step down after eight years as CEO, with a successor search underway while the company reaffirms confidence in ...

It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through ...

Wegovy and Ozempic-maker Novo Nordisk said today its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug ...

Novo Nordisk (NVO) is in focus on Friday after its long-time chief executive Lars Fruergaard Jørgensen announced his ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will step down after eight years at the helm, as the Danish pharmaceutical giant ...

Lars Fruergaard Jørgensen is stepping down as Novo Nordisk CEO, with the company citing its stock's recent struggles.

The CEO of Danish pharmaceutical giant Novo Nordisk, known for its blockbuster weight-loss drug Ozempic, will step down, the ...

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down per mutual agreement with the company. The company said Friday he ...

Investors may get a second bite at the apple, and a second chance to buy this GLP-1 drug leader at a discount price.

Shares of Novo Nordisk (NYSE: NVO) fell 3% today following the announcement that CEO Lars Fruergaard Jørgensen will step down ...